Pfizer Inc. (NYSE:PFE) Shareholders to Collect $0.43 Quarterly Dividend

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Tuesday, October 6th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th.

Pfizer has decreased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 16 years. Pfizer has a dividend payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.

Pfizer Trading Up 0.3%

Shares of PFE stock opened at $27.48 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer has a twelve month low of $23.62 and a twelve month high of $29.21. The company’s 50-day moving average price is $27.50 and its 200-day moving average price is $26.48. The stock has a market cap of $156.63 billion, a price-to-earnings ratio of 36.16, a PEG ratio of 1.84 and a beta of 0.32.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $0.78 earnings per share. Pfizer’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer will post 2.98 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. HSBC lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Guggenheim decreased their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.56.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.